English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A patient who post-operatively develops hyperkalemia is treated with sodium zirconium cyclosilicate (Lokelma ® ), a novel agent used for the treatment of non-life-threatening hyperkalemia with reduced side effects as compared with its predecessors. On CT imaging of the chest, abdomen, and pelvis, a radiopaque fluid is noticed despite the patient not having received any oral or intravenous contrast nor any medications or supplements that may appear radiopaque. Based on previous CT imaging of zirconium-based tooth implants and their radiopaque appearance on images, it is hypothesized that the sodium zirconium cyclosilicate that the patient was administered is the explanation of the radiopacity on CT imaging. We performed an in-vitro experiment to confirm that Lokelma is radiopaque to support our hypothesis. It is important to fully understand the differential of what may cause different appearances on imaging as well as to eliminate potential sources of artifact prior to imaging, or alternatively, to potentially be able to use medications with known radiopaque properties as alternatives to contrast agents.

Radiopacity of sodium zirconium cyclosilicate on CT imaging